Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Catalano

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Rheumatology International|January 1, 1983
Antibodies to Epstein-Barr virus associated antigens in Pima Indians with and without rheumatoid arthritisS F Slovin, T T Kuberski, D A Carson, et al.
The Journal of Clinical Investigation|August 1, 1977
Metabolism of autologous and homologous IgG in rheumatoid arthritisM A Catalano, E H Krick, D H De Heer, et al.
The Journal of Rheumatology|May 1, 1990
A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritisH A Bird, P Le Gallez, J S Dixon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1981
Discordant expression of 2 Epstein-Barr virus-associated antigens, EBNA and RANA, in man-rodent somatic cell hybridsS F Slovin, M C Glassy, T Dambaugh, et al.
The Journal of Rheumatology|April 1, 1989
A clinical and biochemical assessment of prinomide in patients with rheumatoid arthritisH A Bird, J Hill, J S Dixon, et al.
The Journal of Clinical Investigation|October 1, 1992
Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitorN G McElvaney, H Nakamura, P Birrer, et al.
Critical Care Medicine|January 1, 1994
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trialC J Fisher, G J Slotman, S M Opal, et al.
Cytokine|September 1, 1992
Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humansE V Granowitz, R Porat, J W Mier, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1995
Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in manT van der Poll, K J Van Zee, E Endert, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Rheumatology International|January 1, 1983
Antibodies to Epstein-Barr virus associated antigens in Pima Indians with and without rheumatoid arthritisS F Slovin, T T Kuberski, D A Carson, et al.
The Journal of Clinical Investigation|August 1, 1977
Metabolism of autologous and homologous IgG in rheumatoid arthritisM A Catalano, E H Krick, D H De Heer, et al.
The Journal of Rheumatology|May 1, 1990
A clinical and biochemical assessment of a nonthiol ACE inhibitor (pentopril; CGS-13945) in active rheumatoid arthritisH A Bird, P Le Gallez, J S Dixon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 1, 1981
Discordant expression of 2 Epstein-Barr virus-associated antigens, EBNA and RANA, in man-rodent somatic cell hybridsS F Slovin, M C Glassy, T Dambaugh, et al.
The Journal of Rheumatology|April 1, 1989
A clinical and biochemical assessment of prinomide in patients with rheumatoid arthritisH A Bird, J Hill, J S Dixon, et al.
The Journal of Clinical Investigation|October 1, 1992
Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitorN G McElvaney, H Nakamura, P Birrer, et al.
Critical Care Medicine|January 1, 1994
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trialC J Fisher, G J Slotman, S M Opal, et al.
Cytokine|September 1, 1992
Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humansE V Granowitz, R Porat, J W Mier, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1995
Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in manT van der Poll, K J Van Zee, E Endert, et al.
Pageof 2